Collaboration to simplify cell therapy manufacturing 

Cellular Origins, a company focused on enabling scalable and efficient manufacture of cell and gene therapies (CGTs), has announced a collaborative partnership with ScaleReady, a joint venture between Bio-Techne, Fresenius Kabi and Wilson Wolf that brings together process development expertise, tools and technologies for scalable CGT manufacturing.  

The partnership aims to automate portions of ScaleReady’s CGT manufacturing workflow by using Cellular Origin’s robotic system for sterile liquid transfer. 

Cellular Origins’ and ScaleReady’s first project will be to standardise and automate interconnections between the modules of ScaleReady’s G-Rex, a manufacturing platform used by therapy developers internationally to produce CGTs for clinical trials, including the most recently approved commercial therapies. This integration of Cellular Origins’ robotic system will eliminate variability in manual connection techniques. Further projects will automate additional components of ScaleReady’s workflow, such as the robotic movement of G-Rex into and out of incubators.  

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free